SCHEMBL31652736

SCHEMBL31652736

O=C(O)[C@H](c1ccccc1)N1Cc2ccccc2C1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.62
GAA P10253 1/20 0.61
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 2/20 0.57
ALOX15 P16050 1/20 0.57
TSHR P16473 1/20 0.57
XIAP P98170 1/20 0.57
HKDC1 Q2TB90 1/20 0.57
HSD17B10 Q99714 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
CYP2D6 P10635 1/20 0.43
SRC P12931 1/20 0.43
NOTUM Q6P988 1/20 0.42
THRB P10828 1/20 0.42
MAPK1 P28482 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KCNH2 Q12809 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31652570 1.00 LMNA (0.62) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL31652653 1.00 LMNA (0.62) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL2949227 0.88 LMNA (0.58) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL4629091 0.86 LMNA (0.56) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL5213186 0.85 LMNA (0.64) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL31652758 0.84 CPN1 (0.47) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL31652506 0.83 LMNA (0.49) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL2837857 0.82 HDAC3 (0.50) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL31652444 0.81 KMT2A (0.66) LMNAGAAALDH1A1KDM4EALOX15
SCHEMBL31652566 0.81 KMT2A (0.66) LMNAGAAALDH1A1KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213735-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF RADIONETICS ONCOLOGY, INC. 2025-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213735-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF NPY1R, NPY2R, NPY4R LMNA 3809/4885GAA 3092/4885ALDH1A1 3906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.